Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
ГУ Запорожская медицинская академия последипломного образования Минздрава Украины
Список исп. литературыСкрыть список 1. Вайсерман А.М., Войтенко В.П., Мехова Л.В. Эпигенетическая эпидемиология возрастзависимых заболеваний. Онтогенез. 2011; 42 (1): 30–50. 2. Голимбет В.Е., Корень Е.В. Вариации числа копий в геноме – новая страница в генетических исследованиях в области психиатрии: международный проект PsychCNVs. Журн. неврол. и психиатр. 2010; 1: 107–9. 3. Abdolmaleky HM, Cheng KH, Faraone SV et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Gen 2006; 15: 3132–45. 4. Abdolmaleky HM, Cheng KH, Russo A et al. Hypermethylation of the reelin (RELN) promoter in the brain of schizophreniс patients: a preliminary report. Am J Med Gen. Neuropsychiat Gen 2005; 134 (1): 60–6. 5. Abdolmaleky HM, Thiagalingam S. Can the schizophrenia epigenome provide clues for the molecular basis of pathogenesis? Epigenom 2011; 3 (6): 679–83. 6. Abdolmaleky HM, Yaqubi S, Papageorgis P et al. Epigenetic dysregulation of HTR2A in the brain of patients with schizophrenia andbipolar disorder. Schizophr Res 2011; 129 (2–3): 183–90. 7. Abdolmaleky HM, Zhou JR, Thiagalingam S et al. Epigenetic and pharmacoepigenomic studies of major psychoses and potentials for therapeutics. Pharmacogenomics 2008; 9 (12): 1809–23. 8. Addington M, Gornick M, Duckworthetal J. GAD1 (2q31.1), which encodes glutamic acid decarboxylase (GAD67), is associated with childhood-onset schizophrenia and cortical graymatter volume loss. Mol Psychiat 2005; 10 (6): 581–8. 9. Akbarian S, Huang HS. Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders. Brain Research Rev 2006; 52 (2): 293–304. 10. Akbarian S, Kim JJ, Potkin SG et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Archiv Gen Psychiat 1995; 52 (4): 258–78. 11. Akbarian S, Ruehl MG, Bliven E et al. Chromatin alterations associated with down-regulated metabolic gene expression in the prefrontal cortex of subjects with schizophrenia. Arch Gen Psychiat 2005; 62 (8): 829–40. 12. Akhtar A, Cavalli G. The epigenome network of excellence. PloS Biol 2005; 3 (5): е177. 13. Allen NC, Bagade S, McQueen MB et al. Systematic meta-analyses and field synopsis of genetic association studies in schizophrenia: the SzGene database. Nat Gen 2008; 40: 827–34. 14. Amminger PG, Schäfer MR, Papageorgiou P et al. Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders. A randomized, placebo-controlled trial. Arch Gen Psychiat 2010; 67: 146–54. 15. Anderson CA, Soranzo N, Zeggini E, Barrett JC. Synthetic associations are unlikely to account for many common disease genome-wide association signals. PLoS Biol 2011; 9: e1000580. 16. Anthony JC. The promise of psychiatric enviromics. Brit J Psychiat 2001; 178 (40): s8–11. 17. Arnold SE, Talbot K, Hahn CG. Neurodevelopment, neuroplasticity, and new genes for schizophrenia. Prog Brain Res 2005; 147: 319–45. 18. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiat 2002; 7: 405–11. 19. Bassett AS. Parental origin, DNA structure, and the schizophrenia spectrum. Am J Psychiat 2011; 168 (4): 350–3. 20. Bassett AS, Costain G, Fung WL et al. Clinically detectable copy number variations in a Canadian catchment population of schizophrenia. J Psychiat Res 2010; 44: 1005–9. 21. Bassett AS, Scherer SW, Brzustowicz LM. Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease. Am J Psychiat 2010; 167: 899–14. 22. Bertocci B, Miggiano V, Da Prada M et al. Human catechol-O-methyltransferase: cloning and expression of themembrane-associated form. Proc Natl Acad Sci USA 1991; 88: 1416–20. 23. Bertram L. Genetic research in schizophrenia: new tools and future perspectives. Schizophr Bull 2008; 34: 806–12. 24. Beveridge NJ, Gardiner E, Carroll AP et al. Schizophrenia is associated with an increase in cortical microRNA biogenesis. Mol Psychiat 2010; 15 (12): 1176–89. 25. Beveridge NJ, Tooney PA, Carroll AP et al. Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Gen 2008; 17 (8): 1156–68. 26. Bilder RM, Volavka J, Lachman HM, Grace AA. The catechol-O-methyltransferase polymorphism: relations to the tonic-phasic dopamine hypothesis and neuropsychiatric phenotypes. Neuropsychopharmacol 2004; 29: 1943–61. 27. Bobetsis YA, Barros SP, Lin DM et al. Altered gene expression in murine placentas in aninfection-induced intrauterine growth restriction model: a microarray analysis. J Repr Immun 2010; 85: 140–8. 28. Borecki IB, Province MA. Linkage and association: basic concepts. Adv Gen 2008; 60: 51–74. 29. Bornovalova MA, Hicks BM, Iacono WG, McGue M. Familial transmission and heritability of childhood disruptive disorders. Am J Psychiat 2010; 167: 1066–74. 30. Bray NJ, Markus Leweke F, Kapur S, Meyer-Lindenberg A. The neurobiology of schizophrenia: new leads and avenues for treatment. Cur Opin in Neurobiol 2010; 20: 810–5.